New national healthcare research hub for LAT’S

research hub for lat's

New national healthcare research hub for LAT’S: University of Liverpool, aims to position the UK as a world leader in the emerging global field of long-acting therapeutics (LATs). LATs are set to transform how we treat diseases and manage health conditions by replacing weeks or even months of pill taking with a single administered dose. […]

Read More… from New national healthcare research hub for LAT’S

Liverpool Launches £8.2M Medicines Fellowship

research hub for lat's

University of Liverpool leads new £8.2M medicines development fellowship programme: The University of Liverpool is to lead an exciting new MRC-funded medicines career development partnership with Queen Mary University London, the University of Glasgow, the University of Manchester, and a number of industry partners. The Medical Research Council (MRC) Medicines Development Fellowship Programme will strengthen […]

Read More… from Liverpool Launches £8.2M Medicines Fellowship

Global Antibiotic Research and Development Partnership

Global Antibiotic Research

Global Antibiotic Research and Development Partnership: The University of Liverpool and the Global Antibiotic Research and Development Partnership (GARDP) have signed a Memorandum of Understanding to collaborate on new projects to address antimicrobial resistance (AMR) for the benefit of public health. Since 2018, GARDP and the University of Liverpool have been working together to advance new […]

Read More… from Global Antibiotic Research and Development Partnership

Synthetic antibiotics could save millions of lives

synthetic

Liverpool scientists develop synthetic antibiotics that could save millions of lives: University of Liverpool scientists have taken a significant step towards unlocking the medical potential of a new class of potent antibiotic capable of killing ‘superbugs’ including MRSA without detectable resistance. The researchers have developed simplified synthetic versions of the molecule teixobactin, used by producer bacteria […]

Read More… from Synthetic antibiotics could save millions of lives

Wesleyan RSM trainee of the year finalist: Dr Jonathan Evans

Meet the finalist | Dr Jonathan Evans  RSM Coloproctology Section  Presentation title:  The Nrf2 inhibitor Brusatol is a potent antitumour agent, and enhances irinotecan cytotoxicity, in an orthotopic mouse model of colorectal cancer. Focus on colorectal cancer  Currently a specialist trainee in general surgery, with a sub-specialty interest in colorectal, Dr Jonathan Evans studied medicine at the University of Liverpool. […]

Read More… from Wesleyan RSM trainee of the year finalist: Dr Jonathan Evans